Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Syndesi launches as spin-off from UCB
by Michael McCoy
February 12, 2018
| A version of this story appeared in
Volume 96, Issue 7
Syndesi Therapeutics has launched with about $21 million in funding from investors including UCB and Johnson & Johnson. Based at J&J’s JLINX incubator in Beerse, Belgium, Syndesi will develop small molecules licensed from UCB that modulate the synaptic vesicle protein SV2A. UCB markets the SV2A modulator levetiracetam as an epilepsy treatment. The compounds that went to Syndesi are not antiepileptic but have what Syndesi calls procognitive properties that could treat neurological disorders such as Alzheimer’s disease.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X